טוען...
Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity
Inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinases,such as erlotinib and gefitinib, have not been very effective in the treatment of breast cancer although many breast cancer cells express EGFR. To address this apparent paradox, we examined possible predictors of the sensitivity...
שמור ב:
| Main Authors: | , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2007
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2603172/ https://ncbi.nlm.nih.gov/pubmed/17671085 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-06-0514 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|